Results of the KLEAN Study
Results of the KLEAN Study
Pablo Barreiro
Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain
*Correspondence: Pablo Barreiro, Email not available
Abstract
Data from the recently completed lopinavir/r vs.fosamprenavir/r with lamivudine and abacavir in antiretroviral-naive patients were published last August(Eron, et al. Lancet 2006; 368: 476-82) and presentedat the International AIDS Conference thesame month in Toronto, Canada. This randomized,48-week study has compared ritonavir-boostedfosamprenavir with the (up to now preferred) ritonavir-boosted protease inhibitor, lopinavir, both coadministered with the fixed-dose NRTI combination ofabacavir and lamivudine.
